Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma

✍ Scribed by M. Har-Noy; M. Zeira; L. Weiss; E. Fingerut; R. Or; S. Slavin

• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 846 KB
• Volume: 33
• Category: Article
• ISSN: 0145-2126
• DOI: 10.1016/j.leukres.2008.08.017

✦ Synopsis

The breaking of peripheral T-cell tolerance toward self-antigens expressed by tumor cells and the subsequent establishment of an effective tumor protective immune response remains a major challenge for cancer immunotherapy. We report that both protective and therapeutic anti-tumor immune responses can be achieved in a mouse leukemia/lymphoma tumor model through the strong adjuvant effects provided by allogeneic CD3/CD28 cross-linked Th1 memory cells. The adjuvant effect of these cells is mediated by their ability to produce a variety of 'danger signals' which serve to deviate native non-protective Th2 anti-leukemia immune responses to effective Th1 immune responses.